Filipiinid - inglise - FDA (Food And Drug Administration)

h & b pharma international, inc.; distributor: r-merck drug, inc. - vancomycin (as hydrochloride) - powder for injection - 500 mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme (uk) ltd - hepatitis a virus inactivated - suspension for injection

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - hepatitis a virus inactivated - suspension for injection

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - hepatitis a virus inactivated - suspension for injection

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - strain cr 326f hepatitis a virus, inactivated 50 u - solution for injection - 50iu/1ml units/ml - hepatitis vaccines

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - hepatitis a vaccine - solution for injection - 25iu/0.5 m units/ml - hepatitis vaccines

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - strain cr 326f hepatitis a virus, inactivated 50 u - suspension for injection in pre-filled syringe - 50 u/1 millilitre(s) - hepatitis vaccines; hepatitis a, inactivated, whole virus

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - strain cr 326f hepatitis a virus, inactivated 50 u - suspension for injection in pre-filled syringe - 25 u/0.5 millilitre(s) - hepatitis vaccines; hepatitis a, inactivated, whole virus

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

organon usa inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 45 mg - remeron/remeronsoltab are indicated for the treatment of major depressive disorder (mdd) in adults [see clinical studies (14)] . remeron/remeronsoltab is contraindicated in patients: - taking, or within 14 days of stopping, maois (including the maois linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see warnings and precautions (5.3), drug interactions (7)] . - with a known hypersensitivity to mirtazapine or to any of the excipients in remeron/remeronsoltab. severe skin reactions, including stevens-johnson syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have been reported following the use of remeron/remeronsoltab [see adverse reactions 6.2]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for antidepressants at 1-844-405-6185 or

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 30 mg - remeron® (mirtazapine) tablets are indicated for the treatment of major depressive disorder. the efficacy of remeron in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. the effectiveness of remeron in hospitalized depressed